Study Demonstrates Elacestrant Benefit Is Maintained Regardless of ESR1 Mutation Levels

Erica L. Mayer

Study Demonstrates Elacestrant Benefit Is Maintained Regardless of ESR1 Mutation Levels

SABCS 2024 - Breast Cancer Faculty Commentary

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Boston, MA

Dr Erica Mayer discusses an analysis of the EMERALD study, which explores the effects of variant allele frequencies on outcomes for patients with advanced breast cancer being treated with elacestrant.

Breast Cancer Coverage Brought to You By

Study Demonstrates Elacestrant Benefit Is Maintained Regardless of ESR1 Mutation Levels

Sponsored by

Breast Cancer Coverage Brought to You By

Study Demonstrates Elacestrant Benefit Is Maintained Regardless of ESR1 Mutation Levels

Related Items

Sponsored by